Departamento de Ciencias Fisiológicas, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Alameda 340, Santiago, Chile.
Biol Res. 2009;42(3):377-89. Epub 2009 Nov 2.
Angiogenesis, the development of new capillary vessels, has a host of clinical manifestations. The identification of agents that increase or decrease angiogenesis is of great pharmaceutical interest. Classically, in vitro angiogenesis utilizes human umbilical vein endothelial cells (HUVEC) grown in matrigel. This valid and simple method has the drawbacks that each cell population is distinct and the constraint of obtaining primary source material. Herein we utilize the established EA.hy926 endothelial cell line as our model for in vitro angiogenesis and present a novel formula to quantify endothelial cell remodeling to identify pro- and anti-angiogenic agents. Furthermore, our technique details the procedures to identify and quantify compounds that have the capacity to generate pro- or anti-angiogenic factors when given to non-endothelial cells, which we define herein as angiogenic potential. In conclusion, we propose a novel formula that we are confident accurately reflects the degree of in vitro angiogenesis allowing the quantification of prospective angiogenic compounds.
血管生成，即新毛细血管的发育，具有多种临床表现。鉴定能够增加或减少血管生成的物质具有重要的药物学意义。传统上，体外血管生成利用在基质胶中生长的人脐静脉内皮细胞（HUVEC）。这种有效且简单的方法存在每个细胞群体都不同和获得原代材料的限制的缺点。在此，我们利用已建立的 EA.hy926 内皮细胞系作为体外血管生成的模型，并提出了一种新的公式来量化内皮细胞重塑，以鉴定促血管生成和抗血管生成剂。此外，我们的技术详细说明了鉴定和量化化合物的程序，这些化合物在给予非内皮细胞时具有产生促血管生成或抗血管生成因子的能力，我们将其定义为血管生成潜能。总之，我们提出了一种新的公式，我们有信心该公式能准确反映体外血管生成的程度，从而能够定量分析有前景的血管生成化合物。
